SOUTH SAN FRANCISCO, Calif., Oct. 16, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it will present a company overview at the 14th Annual BIO Investor Forum. The BIO Investor Forum will be held October 20-21 at the Parc 55 Hotel in San Francisco. OXiGENE is scheduled to present on Tuesday, October 20 at 4:00 pm Pacific time.
To listen to a live or an archived version of the audio webcast, please visit the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations." A replay of the webcast will be available approximately one hour after the conclusion of the live event.
OXiGENE is a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) to treat cancer. VDAs selectively disrupt abnormal blood vessels that sustain tumors. The company's investigational drugs include CA4P (fosbretabulin), which is in development as a treatment for solid tumors, and OXi4503, which is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: email@example.com 650-635-7000